Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOBLE: Neoadjuvant Olaparib and Durvalumab in TNBC
NCT05209529Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2024
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of olaparib, durvalumab in triple-negative breast cancer (TNBC), sponsored by European Organisation for Research and Treatment of Cancer. Planned start Feb 2024; status: withdrawn.
02
Drugs
olaparibdurvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05209529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05209529.